Prenatal Exposure to Methamphetamine and Its Association With Birth Outcomes: A Meta-Analysis

Nima Rastegar-Pouyani1, Fatemeh Fakhari1, Armineh Rezagholi Lalani2

  • 1Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

PubMed

Insights

Prenatal methamphetamine exposure significantly increases the risk of preterm birth (PTB), low birth weight (LBW), and being small for gestational age (SGA). This systematic review highlights critical public health concerns regarding substance use during pregnancy.

Area of Science:

  • Public Health
  • Perinatal Medicine
  • Toxicology

Background:

  • Methamphetamine abuse is a growing global public health concern.
  • Prenatal exposure to methamphetamine poses significant risks to fetal development and newborn health.

Purpose of the Study:

  • To systematically review and meta-analyze the association between prenatal methamphetamine exposure and adverse birth outcomes.
  • To evaluate risks for Preterm Birth (PTB), Low Birth Weight (LBW), and Small for Gestational Age (SGA).

Main Methods:

  • Systematic literature search of PubMed, Web of Science, and Scopus (up to Dec 2021).
  • Meta-analysis of eight observational studies using Odds Ratios (OR) and 95% Confidence Intervals (CI).
  • Assessed heterogeneity, publication bias, and performed sensitivity analysis.

Main Results:

  • Prenatal methamphetamine exposure is associated with a 2.64 times higher risk of PTB (OR 2.64; 95% CI 1.89-3.70).
  • Associated with a 2.83 times higher risk of LBW (OR 2.83; 95% CI 1.09-7.38).
  • Associated with a 1.44 times higher risk of SGA (OR 1.44; 95% CI 1.04-1.99).

Conclusions:

  • A substantial association exists between prenatal methamphetamine exposure and PTB, LBW, and SGA.
  • Findings underscore the critical need for interventions addressing prenatal methamphetamine use.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.5K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
307
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
360